Evaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine
dc.contributor.author | Yakubogullari N. | |
dc.contributor.author | Coven F.O. | |
dc.contributor.author | Cebi N. | |
dc.contributor.author | Coven F. | |
dc.contributor.author | Coven N. | |
dc.contributor.author | Genc R. | |
dc.contributor.author | Bedir E. | |
dc.contributor.author | Nalbantsoy A. | |
dc.date.accessioned | 2024-07-22T08:06:18Z | |
dc.date.available | 2024-07-22T08:06:18Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Astragaloside VII (AST-VII), a major cycloartane saponin isolated from Turkish Astragalus species, turned out to be one of the most active metabolites demonstrating Th1/Th2 balanced immune response. As Quillaja saponins are extensively used in adjuvant systems, this study made an attempt to improve AST-VII based adjuvant systems by using different immunostimulatory/delivery agents (monophosphoryllipid A (MPL), Astragalus polysaccharide (APS) and squalene) and to induce cellular and humoral immune response against a viral vaccine. For this purpose, Newcastle Disease vaccine (NDV) was chosen as a model vaccine. Swiss albino mice were immunized subcutaneously with LaSota vaccines in the presence/absence of AST-VII or developed adjuvant systems. AST-VII administration both in live/inactivated LaSota vaccines induced neutralizing and NDV specific IgG, IgG1 and IgG2b antibodies response as well as IL-2 and IL-4 production. APS based delivery systems enhanced the production of neutralizing antibody and the minor augmentation of IFN-γ and IL-2 levels. Squalene emulsion (SE) alone or combined with AST-VII were effective in NDV restimulated splenocyte proliferation. As a conclusion, AST-VII and AST-VII containing adjuvant systems demonstrated Th1/Th2 balanced antibody and cellular immune responses in NDV vaccines. Thus, these systems could be developed as vaccine adjuvants in viral vaccines as alternative to saponin-based adjuvants. © 2021 International Alliance for Biological Standardization | |
dc.identifier.DOI-ID | 10.1016/j.biologicals.2021.01.005 | |
dc.identifier.issn | 10451056 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13467 | |
dc.language.iso | English | |
dc.publisher | Academic Press | |
dc.rights | All Open Access; Green Open Access | |
dc.subject | Adjuvants, Immunologic | |
dc.subject | Animals | |
dc.subject | Antibodies, Neutralizing | |
dc.subject | Antibodies, Viral | |
dc.subject | Interferon-gamma | |
dc.subject | Interleukin-2 | |
dc.subject | Mice | |
dc.subject | Newcastle Disease | |
dc.subject | Saponins | |
dc.subject | Squalene | |
dc.subject | Vaccines, Attenuated | |
dc.subject | Vaccines, Inactivated | |
dc.subject | Viral Vaccines | |
dc.subject | astragaloside VII | |
dc.subject | bacterial polysaccharide | |
dc.subject | gamma interferon | |
dc.subject | immunoglobulin G | |
dc.subject | immunoglobulin G1 | |
dc.subject | immunoglobulin G2b | |
dc.subject | immunostimulating agent | |
dc.subject | interleukin 2 | |
dc.subject | interleukin 4 | |
dc.subject | monophosphoryllipid A | |
dc.subject | neutralizing antibody | |
dc.subject | Newcastle disease vaccine | |
dc.subject | saponin | |
dc.subject | squalene | |
dc.subject | unclassified drug | |
dc.subject | astragaloside VII | |
dc.subject | gamma interferon | |
dc.subject | immunological adjuvant | |
dc.subject | inactivated vaccine | |
dc.subject | interleukin 2 | |
dc.subject | live vaccine | |
dc.subject | neutralizing antibody | |
dc.subject | saponin | |
dc.subject | squalene | |
dc.subject | virus antibody | |
dc.subject | virus vaccine | |
dc.subject | animal cell | |
dc.subject | antibody response | |
dc.subject | Article | |
dc.subject | cell function | |
dc.subject | cell proliferation | |
dc.subject | controlled study | |
dc.subject | cytokine production | |
dc.subject | drug design | |
dc.subject | drug screening | |
dc.subject | emulsion | |
dc.subject | female | |
dc.subject | hemagglutination inhibition | |
dc.subject | humoral immunity | |
dc.subject | immune response | |
dc.subject | immunization | |
dc.subject | male | |
dc.subject | mouse | |
dc.subject | Newcastle disease | |
dc.subject | nonhuman | |
dc.subject | priority journal | |
dc.subject | spleen cell | |
dc.subject | virus neutralization | |
dc.subject | animal | |
dc.subject | immunology | |
dc.subject | Newcastle disease | |
dc.title | Evaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine | |
dc.type | Article |